Novel Endocrine Therapy Giredestrant Improves Disease-free Survival Over Standard of Care for Patients With Early-stage Breast Cancer in Phase III lidERA Trial / American Association for Cancer Research

Kathleen Medora / aacr - SAN ANTONIO – The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine ther…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Brian Lawenda: Visual Decision Aid To Simplify Breast Cancer Treatment Choices for Women 65+

3 months / oncodaily

Runcie Chidebe: Fatima Cardoso Presents the Advanced Breast Cancer Global Decade Report 2015–2025

3 months / oncodaily

Adrian Lee: Global Research Focus on Lobular Breast Cancer at SABCS 2025

3 months / oncodaily

SABCS 2025: Tissue-Free ctDNA Surveillance Anticipates Relapse in High-Risk Early TNBC

3 months / oncodaily

Clinical characteristics and prognostic impact of HER2 low expression in breast cancer subtypes from a Brazilian real-world cohort

3 months / nature

Aydah AlAwadhi: Survivorship in Young Women with Breast Cancer is Complex

3 months / oncodaily

20 Posts Not to Miss from SABCS 2025, Part 2

3 months / oncodaily

Sibylle Loibl: Thrilled to be Back in San Antonio for SABCS 2025

3 months / oncodaily

Aleix Prat: New HER2DX Data at SABCS 2025

3 months / oncodaily

Matthew Oberley: Caris Life Sciences Unveils AI Driven Breast Cancer Recurrence Risk Project at SABCS 25

3 months / oncodaily

Paolo Tarantino: Not All Residual Disease Is Equal in TNBC

3 months / oncodaily

Harold J. Burstein: SGBCC Consensus Guideline for Early Breast Cancer

3 months / oncodaily

Novel endocrine therapy improves disease-free survival over standard of care for patients with early-stage breast cancer

3 months / medicalxpress

Novel Endocrine Therapy Giredestrant Improves Disease-free Survival Over Standard of Care for Patients With Early-stage Breast Cancer in Phase III lidERA Trial

3 months / aacr / Kathleen Medora

A historic step towards a smokefree Wales

3 months / cancerresearchuk / Cancer Research UK

Wednesday, December 10, 2025, 11:22 am / permalink 16789 / 15 stories in 3 months



Related Stories



Related Tags


Healthcare

EPA proposes rollback on ethylene oxide sterilizer emissions (36 min)

Two deaths prompt probe of paid plasma donation clinics in Winnipeg (1 hr)

HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (18 hrs)

more #healthcare


Pharmaceuticals

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (19 hrs)

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (22 hrs)

FDA approves leucovorin for rare folate disorder despite autism hype (34 hrs)

more #pharmaceuticals


Public Health

EPA proposes rollback on ethylene oxide sterilizer emissions (36 min)

Two deaths prompt probe of paid plasma donation clinics in Winnipeg (1 hr)

Vitamin D trial shows reduced long‑COVID risk but no severity benefit (21 hrs)

more #publichealth


StackHealth Time Machine



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.